| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chief Medical Officer
1 company
Steven Zelenkofske last filed a Form 4 in January 2025, as Chief Medical Officer at QURE. Steven Zelenkofske's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
At the last filing, the largest reported position was 159,458 shares of QURE. The QURE filings lean toward selling, a net 23,929 shares.
Steven Zelenkofske has 5 Form 4 filings on record from June 2017 to January 2025, across 2 companies: Director at Cadrenal Therapeutics (CVKD), 2024–2025; Chief Medical Officer at uniQure (QURE), 2017–2018.
The 6 reported transactions were 3 option or other derivative awards, 2 stock awards and 1 open-market sale.
Counted by filing, the open-market trades come to no purchases and 1 sale worth about $889K.
The only open-market sale was 23,929 shares of QURE at an average $37.14 on June 6, 2018, about $889K.
Shares as reported in the last Form 4 for each company; the most recent is from January 2025. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Jun 6, 2018 | QURE Uniqure N.V. | Chief Medical Officer | Sell | 23,929 | $37.14 | $888,723.06 | -13.0% |